StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences DTA — Stock-based compensation by Year

DTA — Stock-based compensation ($M) ($M)

Gilead Sciences DTA — Stock-based compensation: $83M in FY2025, down 1.2% from a year earlier. That is the lowest of the 12 years on record here.

Latest, FY2025
83
Period ended Dec 31, 2025
Change on a year earlier
-1.2%
84 in FY2024
History
12 years
Since FY2014
Sources
10
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-K Note 15.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDTA — Stock-based compensation ($M) ($M)Year on yearSource
FY2025Dec 31, 202583-1.2%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 202484-10.6%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 202394-1.1%Form 10-K (filed 2025-02-28) ↗
FY2022Dec 31, 202295-18.8%Form 10-K (filed 2024-02-23) ↗
FY2021Dec 31, 2021117+3.5%Form 10-K (filed 2023-02-22) ↗
FY2020Dec 31, 20201130.0%Form 10-K (filed 2022-02-23) ↗
FY2019Dec 31, 2019113-30.7%Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 2018163-1.2%Form 10-K (filed 2019-02-26) ↗
FY2017Dec 31, 2017165-22.2%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 2016212-4.5%Form 10-K (filed 2018-02-27) ↗
FY2015Dec 31, 2015222+41.4%Form 10-K (filed 2017-02-27) ↗
FY2014Dec 31, 2014157–Form 10-K (filed 2016-02-24) ↗

Cite this data

StockData. (2026). Gilead Sciences DTA — Stock-based compensation ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/dta-sbc-row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.